( h at least 1 follow-up visit after Mont...)New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine,Health

h at least 1 follow-up visit after Month 7. Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up. Note 2: The first analysis in the table (i.e., HPV 16- or 18-related CIN 2/3, AIS or worse) was the primary endpoint of the vaccine development plan. Note 3: FUTURE I refers to Protocol 013; FUTURE II refers to Protocol 015. ---------------------------------------------------------------------- GARDASIL was efficacious against HPV disease caused by each of the 4 vaccine HPV types. In a pre-defined analysis, the efficacy of GARDASIL against HPV 16/18-related disease was 100% (95% CI: 87.9%, 100.0%) for CIN 3 or AIS and 100% (95% CI: 55.5%, 100.0%) for VIN 2/3 or VaIN 2/3. The efficacy of GARDASIL against HPV 6-, 11-, 16-, and 18-related VIN 1 or VaIN 1 was 100% (95% CI: 75.8%, 100.0%). These analyses were conducted in the PPE population that consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy in Subjects with Current or Prior Infection GARDASIL is a prophylactic vaccine. There was no clear evidence of protection from disease caused by HPV types for which subjects were PCR positive and/or seropositive at baseline. Individuals who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types. General Population Impact The general population of young American women includes women who are HPV-naive (PCR negative and seronegative) and women who are HPV-non-naive (PCR positive and/or seropositive), some of whom have HPV-related disease. The clinical trials population approximated the general population of American women wi
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics